
ZVRA Stock Forecast & Price Target
ZVRA Analyst Ratings
Bulls say
Zevra Therapeutics is supported by a stronger-than-expected U.S. commercial thesis for Miplyffa, with claims data and ongoing patient identification suggesting the NPC market may be materially larger than initially assumed. Because Miplyffa is already approved and commercialized in the U.S., the company has a real operating base, is continuing to add patient enrollments, and appears positioned to benefit from a conservatively valued pool of roughly 300-350 diagnosed NPC patients. The setback in Europe reduces near-term optionality, but it does not weaken the core U.S. opportunity, while EU clarity, territory expansion in 3Q, IP extension, and celiprolol development create additional upside drivers into 2026.
Bears say
Zevra Therapeutics is facing a materially weakened fundamental outlook after the EMA reaffirmed its refusal of Meplyffa in NPC, citing concerns about the handling and analysis of the pivotal NPC-002 Phase II/III trial (n=50), lack of clear benefit in ambulation or cognition, and an unconvincing miglustat subgroup effect. The loss of the EU opportunity removes a major upside driver, lowers its approval probability there to 0% from 40%, and strips out EU Miplyffa net sales and related launch costs from FY27E onward, while the probability-adjusted Miplyffa NPV falls to $14/share from $18. Its valuation now depends more heavily on U.S. execution, with FY27E Miplyffa U.S. sales still estimated at $165.0MM and YE26 net cash at $4/share, but the company’s growth case is increasingly concentrated and regulatory risk remains elevated.
This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ZVRA Analyst Forecast & Price Prediction
Start investing in ZVRA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Zevra Therapeutics Inc (ZVRA) Forecast
ZVRA Analyst Forecast & Price Prediction
Start investing in ZVRA
Order type
Buy in
Order amount
Est. shares
0 shares